.jpg)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Aerie Pharma (AERI – Research Report) and Quidel (QDEL – Research Report).
Aerie Pharma (AERI)
Raymond James analyst Elliot Wilbur maintained a Hold rating on Aerie Pharma today. The company’s shares closed last Monday at $15.65.
According to TipRanks.com, Wilbur has 0 stars on 0-5 stars ranking scale with an average return of -3.3% and a 40.9% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Amneal Pharmaceuticals, and Flexion Therapeutics.
Currently, the analyst consensus on Aerie Pharma is a Strong Buy with an average price target of $27.25.
See today’s analyst top recommended stocks >>
Quidel (QDEL)
In a report released today, Andrew Cooper from Raymond James maintained a Buy rating on Quidel. The company’s shares closed last Monday at $122.44, close to its 52-week low of $103.31.
According to TipRanks.com, Cooper is a 3-star analyst with an average return of 10.1% and a 58.8% success rate. Cooper covers the Healthcare sector, focusing on stocks such as Orasure Technologies, Guardant Health, and Myriad Genetics.
Quidel has an analyst consensus of Moderate Buy, with a price target consensus of $146.33, implying a 19.3% upside from current levels. In a report issued on July 8, Piper Sandler also maintained a Buy rating on the stock with a $140.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AERI: